Every 10-Q that RCM Technologies Inc (RCMT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RCMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCMT filings page.
RCM Technologies, Inc. reports solid growth for the thirteen and twenty-six weeks ended July 4, 2026. Quarterly revenue rose to $93.8 million, up from $78.2 million a year earlier, driven mainly by a $13.0 million increase in Engineering and growth in Specialty Health Care and Life Sciences, Data and Solutions. Quarterly net income increased to $4.9 million from $3.8 million, with diluted EPS of $0.68 versus $0.50.
For the twenty-six-week period, revenue reached $176.9 million and net income $8.7 million. Operating cash flow strengthened to $13.5 million, supporting share repurchases of 348,366 shares at an average price of $19.03 and a modest reduction in borrowings under the revolving credit facility to $23.4 million. Cash increased to $6.6 million while total assets stayed roughly flat. The company notes significant customer concentration, with three customers representing up to 23.3%, 13.5% and 13.3% of consolidated revenue, and continues to operate within its expanded credit facility, with $32.7 million of additional borrowing availability.
RCM Technologies reported relatively stable results for the thirteen weeks ended April 4, 2026, with revenue of $83.0 million versus $84.5 million a year earlier. Net income was $3.8 million, down slightly from $4.2 million, and diluted earnings per share were $0.52 compared with $0.54.
Business mix shifted meaningfully. Specialty Healthcare revenue rose to $48.1 million, while Engineering declined to $26.1 million and Life Sciences, Data and Solutions eased to $8.8 million. Gross margin improved modestly to 26.5%, but higher selling, general and administrative expenses kept operating income at $5.9 million versus $6.6 million.
Operating cash flow was $2.7 million, well below the prior period’s $16.7 million, largely due to working-capital swings in receivables and transit balances. The company continued to use its balance sheet actively, repurchasing 348,366 shares at an average price of $19.03 and increasing borrowings on its revolving credit facility to $28.8 million, with $33.3 million of additional availability.
RCM Technologies (RCMT) reported Q3 2025 results with revenue of $70.3 million and diluted EPS of $0.30. Operating income was $3.9 million. For the first thirty‑nine weeks, revenue reached $232.9 million and diluted EPS was $1.34, as operating income rose to $17.1 million.
Growth was led by Engineering (Q3 revenue $31.4 million) and Specialty Health Care ($30.0 million), while Life Sciences, Data & Solutions posted $8.9 million. Gross profit for the quarter was $19.4 million on cost of services of $50.9 million. Two customers represented 19.6% and 13.2% of year‑to‑date revenue, both within Specialty Health Care.
Cash was $1.3 million, borrowings under the line of credit were $31.5 million, and letters of credit outstanding were $13.1 million. The revolving credit facility was amended to $65.0 million with maturity on December 3, 2029. The company repurchased 301,640 shares at an average price of $16.89 during the first thirty‑nine weeks, with $37.1 million remaining under the authorization. Common shares outstanding were 7,410,510 as of November 5, 2025.